CREATE Medicines, cofounded by Siddhartha Mukherjee, closed a $122M Series B to advance in‑vivo CAR‑T candidates for cancer and autoimmune disease.

MIT leaders say federal research cuts and falling grad enrollment forced tighter budgets and fewer admissions — a shift President Sally Kornbluth calls "a striking loss."

State regulators approved Dana-Farber’s roughly $50.5M proton therapy center at Longwood, a compact ambulatory build aimed at expanding pediatric and adult access.

Cambridge-founded OpenEvidence moved its HQ to Miami in 2025 and is expanding across Florida with backing from a national medical society and major investors.

Akamai disclosed a seven‑year, $1.8B cloud commitment; reporting identifies Anthropic as the buyer and shares jumped sharply on the news.

Roche will acquire Boston-based PathAI for $750M up front, with up to $300M in milestone payments. The deal is expected to close in the second half of 2026 and will fold PathAI into Roche Diagnostics.

Mounjaro's Q1 sales topped Keytruda, lifting Lilly's revenue and reshaping the blockbuster drug ranking.

Moderna, Praxis and other Massachusetts firms joined a new national alliance pushing a Vision 2030 plan to keep U.S. biotech competitive with China.

Local drone makers from Charlestown to Wilmington are racing to meet the Pentagon’s Drone Dominance price and production targets. The shift could turn small workshops into defense factories.

Cambridge AI startup Blitzy raised $200M at a $1.4B valuation to scale its agentic platform that rewrites legacy corporate code. Boston investors joined the round as the company hires in Kendall Square.

An AI from Mass General Brigham and MIT can score lung‑cancer risk from one CT up to six years ahead; the model is validated but not yet cleared for routine care.

Vertex and Moderna said Monday they are discontinuing the VX‑522 Phase 1/2 inhaled mRNA trial after persistent lung inflammation concerns, ending a potential option for thousands of CF patients.

A Harvard‑led Science paper found an OpenAI reasoning model outscored physicians on several text‑based diagnostic tasks, but authors say randomized trials are needed before clinical use.